Abstract. We have previously demonstrated that continuous exposure of human HL-60 human promyelocytes to 1-fl-D-arabinofuranosylcytosine (ara-C) results in the induction of terminal differentiation to monocyte-like cells. The present study extends these findings by demonstrating that ara-C induces hemoglobin synthesis in human K562 erythroleukemia cells. This effect occurs maximally at an ara-C concentration (5 X lo-M) that results in K562 cytostasis. In contrast to the reversible effects of hemin and hydroxyurea on globin synthesis in this cell line, we have found that the induction of K562 hemoglobin synthesis by ara-C is irreversible. An induction of K562 hemoglobin synthesis also occurs with aphidicolin, another inhibitor of Sphase DNA synthesis, but not with vinblastine, an inhibitor of mitosis. Finally, ara-C induction of a differentiated K562 phenotype is accompanied by the loss of self-renewal capacity, a finding consistent with terminal differentiation.
Introduction
l-fl-D-arabinofuranosylcytosine (ara-C)' is one of the most effective agents in the treatment of human acute myelogenous leukemia (1) . The basis for this selectivity against leukemic cells has remained unclear. Ara-C incorporates specifically into DNA, but not into RNA, of human myeloblasts (2) . The incorporated ara-C residue behaves as a relative chain terminator, and the extent of ara-C incorporation into DNA correlates significantly with inhibition of DNA synthesis (3) . The inhibition of replicative DNA synthesis by ara-C causes DNA fragmentation (4) . Furthermore, there is a highly significant relationship between the incorporation of ara-C into DNA and the loss of leukemic cell clonogenic survival (2, 5, 6) . These findings have suggested that the incorporation of ara-C into leukemic cell DNA is responsible for cytotoxicity.
An inhibition of DNA synthesis by sublethal doses of ara-C is associated with the induction of differentiation in human promyelocytic leukemic cells (7) . Similar phenotypic changes have been observed with aphidicolin, an inhibitor of DNA polymerase-a, which is not incorporated into DNA (8) . The induction of differentiation by both of these agents has been accompanied by the loss of clonogenic survival, suggesting that terminal differentiation of HL-60 cells can be induced by drugs known to inhibit DNA synthesis. It is not clear, however, whether this effect contributes to decreases in the self-renewal capacity of acute myeloblastic leukemia cells after ara-C treatment (9) .
The K562 human leukemic cell line was established from a patient with chronic myelogenous leukemia (10) . K562 cells can be induced by hemin to form embryonic and fetal hemoglobins (11) (12) (13) . The induction of K562 cells by hemin has been shown to be mediated at a transcriptional level (14) , with increases in both the rate of transcription and the level of accumulation of r-, e-, y-and a-globin messenger RNAs (15) . In contrast, treatment with hydroxyurea has resulted in an increase in the rate of transcription of primarily the t-and E-globin genes (15) . Furthermore, the effects of hemin and hydroxyurea on the induction of K562 globin synthesis have been found to be reversible and therefore not associated with the induction of terminal differentiation (12, 16) .
This report extends our previous findings in HL-60 cells by monitoring the effects of ara-C on the induction of differentiation in K562 cells. The results demonstrate that ara-C is a potent inducer of K562 hemoglobin expression and that, in contrast to the effects hemin and hydroxyurea, this effect is irreversible. Furthermore, the appearance of a differentiated K562 phenotype is associated with the loss of clonogenic survival, suggesting that ara-C treatment results in terminal differentiation. These Gel electrophoresis. Electrophoresis of cell lysates was carried out in sodium dodecyl sulfate (SDS)-15% polyacrylamide gels (18, 19) . Cell lysates were prepared by washing the cell pellets twice in cold phosphate-buffered saline and resuspending them in SDS sample solution (19) . Proteins were detected by staining with Coomassie Brilliant Blue R. X l0-7 M ara-C and declined with higher drug exposures (Fig.   2 ). An absolute increase in benzidine-positive cells excludes the possibility of a selective loss of more rapidly proliferating and undifferentiated cells during drug exposure.
The effects of duration of drug exposure on the induction of benzidine-positive K562 cells were monitored from 24 to 144 h. The increase in percentage of benzidine-positive cells was linear during exposure to 5 X l0-7 M ara-C (Fig. 3) . The induction of K562 hemoglobin synthesis by ara-C was further evaluated by polyacrylamide gel electrophoresis ( (Fig. 4) . These results agree with the increase in benzidine-positive cells after ara-C treatment and support the finding that ara-C, like hemin, induces the synthesis of hemoglobin.
Since the induction of K562 hemoglobin synthesis by hemin and hydroxyurea is reversible, it was of interest to determine whether the removal of ara-C after induction would also result in a loss of detectable globin. K562 cells were exposed to 5 X 10-7 M ara-C for from 12 The irreversible induction of hemoglobin synthesis in K562 cells by ara-C was confirmed by polyacrylamide gel electrophoresis (Fig. 6) . Globin synthesis was detectable in cells treated with ara-C or hemin for 72 h. These cells were then washed free of inducer and maintained in drug-free medium for an additional 3 d. Under these experimental conditions, globin synthesis was detectable in ara-C treated cells but not in the hemin-treated cells. This finding confirms the reversible induction of globin synthesis by hemin and demonstrates the irreversible induction by ara-C.
The irreversible induction of hemoglobin synthesis by ara-C suggested that this effect could be associated with terminal differentiation. The K562 cells were treated with 5 X 10-7 M ara-C for from 12 to 120 h. Cells were then washed free of drug and monitored for clonogenic survival. The results obtained are illustrated in Fig. 7 . A 24-h exposure to ara-C resulted in >70% loss of clonogenic survival, whereas a 48-h exposure reduced self-renewal capacity by >95%. These observations indicate that the induction of hemoglobin synthesis by ara-C is associated with a terminal process.
It was also interesting to compare these effects of ara-C with those of other inhibitors of DNA synthesis. A 5-d exposure to varying concentrations of hydroxyurea (1 0' to 5 X 10-3 M) resulted in -20% benzidine-positive cells (Fig. 8) . In contrast, a 5-d exposure to aphidicolin (5 X 10-7 to 10-3 M) resulted in almost 50% benzidine positive-cells at a concentration of 5 X 10-s M. Maximum induction of benzidinepositive cells occurred at concentrations of hydroxyurea and aphidicolin that resulted in cytostasis. The results obtained with aphidicolin were similar to those obtained with ara-C, whereas both ara-C and aphidicolin were more effective in and precluded the appearance of monocyte differentiation markers. The present studies have monitored the effects of ara-C on the induction of hemoglobin in the K562 erythroleukemia cell line. The results are similar in certain respects to those obtained in our previous studies. Ara-C treatment of K562 cells resulted in the appearance of a differentiated phenotype, as determined by accumulation of hemoglobin. This effect was maximal at an ara-C concentration (5 X 10-' M) that resulted in K562 cytostasis. Higher concentrations of drug resulted in cell lethality and a decrease in the percentage of benzidinepositive cells. Of particular interest is the demonstration that this effect was irreversible, a finding that contrasts with the reversible effects of hemin and hydroxyurea on hemoglobin synthesis in this cell line (12, 16) . More important, the induction of a differentiated K562 phenotype by ara-C was accompanied by the loss of self-renewal capacity, an observation consistent with a process of terminal differentiation.
Previous studies have shown that the inhibition of eukaryotic DNA replication results in an aberrant form of DNA synthesis, with certain segments of DNA being replicated more than once in a single cell cycle (22) (23) (24) . This form of aberrant DNA synthesis occurs after the inhibition of DNA replication by ara-C (22, 23). The additional copies of certain segments of DNA might result in the accumulation of DNA fragments and an alteration of gene expression. We have previously shown that both ara-C and aphidicolin cause an accumulation of DNA strand breaks in replicating DNA (4) . Although it is not clear what mechanism is responsible for altered gene expression during the treatment of HL-60 and K562 cells with ara-C, other inhibitors of S-phase DNA replication, such as aphidicolin and hydroxyurea, can induce similar phenotypic changes. The induction of K562 hemoglobin synthesis, however, has not been detectable after the treatment of these cells with nonlethal concentrations of vinblastine, an inhibitor of mitosis. Studies are in progress to determine more precisely the types of globin chains induced by ara-C and whether these genes are amplified by inhibition of replicative DNA synthesis.
Finally, the induction of leukemia cell differentiation by ara-C and other chemotherapeutic agents known to inhibit DNA synthesis has not as yet been shown to occur in the clinical setting. Thus, the present findings may be limited to human leukemic cell lines established for long-term growth in tissue culture. Although low doses of ara-C have recently been used successfully in the treatment of preleukemia and acute leukemia (25) (26) (27) , this effect probably occurs as a result of clonal selection rather than of induction of terminal differentiation. Further clinical studies are required to address this issue.
